Gallen International Expert Consensus on the “Primary Therapy of Early Breast Cancer 2013” proposed that luminal subtypes of breast cancer can be defined in view of immunohistochemistry (IHC) for ER, progestrone receptor (PR), HER2neu, and ki67 index rather than conventional molecular diagnostics [4]. This evidence concerns the gene PGR and breast carcinoma.